Otonomy, Inc.

Biotechnology valuations generally have been on the rise in recent months, relative to general stock market indices, but there still are a number of drug developers that are having trouble gaining tra

Bogged down by an ongoing spat with its largest shareholder and a share price that continues to flirt with penny stock territory, Mereo BioPharma Group plc announced an updated operating plan on 18

AstraZeneca is to spend around $68m to acquire the beleaguered LogicBio Therapeutics and its gene therapy platform – a generous payout which could provide a template for further deals in the space.

A drug developer went public in the US for the first time in more than two months when MAIA Biotechnology, Inc. raised $10m from the sale of 2 million shares at $5 each on 27 July, taking advantage